US Patent 11873495 Compounds and methods for reducing LRRK2 expression
Patent 11873495 was granted and assigned to Ionis Pharmaceuticals on January, 2024 by the United States Patent and Trademark Office.
All edits
Edits on 19 Jan, 2024
Golden AI
Edits made to:
Infobox (+54 properties)
Article (+521 characters)
US Patent 11873495 Compounds and methods for reducing LRRK2 expression
Article
Patent abstract
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of LRRK2 RNA in a cell or animal, and in certain instances reducing the amount of LRRK2 protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease. Such symptoms and hallmarks include ataxia, neuropathy, and aggregate formation. Such neurodegenerative diseases include Parkinson's disease.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Susan M. Freier0
Tracy A. Cole0
Date of Patent
January 16, 2024
0Patent Application Number
177128220
Date Filed
April 4, 2022
0Patent Citations
Patent Primary Examiner
Find more entities like US Patent 11873495 Compounds and methods for reducing LRRK2 expression
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.